{"id":"W4417187153","doi":"10.1080/14796694.2025.2599082","title":"Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; Jewish General Hospital","funders":"Seagen; Bristol-Myers Squibb","keywords":"Nivolumab; Brentuximab vedotin; Lymphoma; Ipilimumab; Chemoimmunotherapy; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005158092,0.000296535,0.0006602993,0.0001490318,0.0001749102,0.0002453351,0.0003012021,0.0001968685,0.0007176542],"category_scores_gemma":[0.0003031687,0.00009573107,0.0002828983,0.000141551,0.0001307829,0.0002061937,0.0001541117,0.0005380348,0.0002920133],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004120837,"about_ca_system_score_gemma":0.0003633392,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006236203,"about_ca_topic_score_gemma":0.002344557,"domain_scores_codex":[0.9998714,0.00005115587,0.00001352998,0.00001821099,0.0000207491,0.00002496621],"domain_scores_gemma":[0.9998813,0.00002501575,0.00002326959,0.000009557356,0.000009754253,0.00005111639],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.0635852,0.007039931,0.05240812,0.001955695,0.001279048,0.002693891,0.000473603,0.005036755,0.1037329,0.0002221378,0.00605918,0.7555136],"study_design_scores_gemma":[0.09384663,0.3723923,0.3788348,0.0007466624,0.002188562,0.01755131,0.0005561247,0.01901299,0.05750689,0.0007077002,0.05653356,0.0001224211],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906496,0.007159025,0.0003647228,0.0001816486,0.00005341794,0.0001904135,0.0001249453,0.00007948152,0.001196742],"genre_scores_gemma":[0.9971614,0.001418051,0.0004500753,0.0001965472,0.00003861198,0.00004881049,0.0001993473,0.000006837208,0.0004803508],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0007176542,"threshold_uncertainty_score":0.002989829,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009151288919165883,"score_gpt":0.2901132775739707,"score_spread":0.2809619886548048,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}